Peripheral T-cell Lymphoma Forum 2008

 
 
 

The Peripheral T-cell Lymphoma Forum took place September 18-20, 2008, in Washington, DC. The meeting was chaired by Francine M. Foss, MD, of Yale Cancer Center, and Pier Luigi Zinzani, MD, PhD, of University of Bologna.

 

Anti-CD30 agents in PTCL

Frieda Pearce, PhD Read Article
Published: 10/09/08

CD30 is an attractive target for immunotherapy, and 2 new agents targeting the protein could be used to treat T-cell lymphomas, said a presenter at the Peripheral T-cell Lymphoma Forum. Lauren Pinter-Brown, MD, from the Geffen School of Medicine at UCLA, explained why CD30 should be targeted in T-cell lymphomas and discussed 2 agents—SGN-30 and MDX-060—that might be capable of doing the job. [Read Article]

Alemtuzumab improves efficacy of CHOP in T-cell lymphomas

Jane Rosen, PhD Read Article
Published: 10/09/08

Results of a phase 1 trial indicate that alemtuzumab can improve the efficacy of CHOP in patients with T-cell lymphomas. Pierluigi Porcu, MD, of the Comprehensive Cancer Center at Ohio State University, presented these results at the Peripheral T-cell Lymphoma Forum, which took place September 18-20 in Washington, DC. [Read Article]

The Japanese experience treating PTCL

Frieda Pearce, PhD Read Article
Published: 10/09/08

Kensei Tobinai, MD, PhD
Kensei Tobinai, MD, PhD

Recent studies have helped to increase survival rates in patients with T-cell lymphomas, but more work needs to be done, according to a speaker at the Peripheral T-cell Lymphoma Forum. Kensei Tobinai, MD, PhD, from the National Cancer Center Hospital in Tokyo, presented 3 studies that represent the Japanese experience of treating adult T-cell leukemia/lymphoma (ATLL) and nasal NK/T-cell lymphoma. [Read Article]

NF-kappa B plays key role in hematologic malignancies

Jane Rosen, PhD Read Article
Published: 10/06/08

Arnold Rabson, MD
Arnold Rabson, MD

NF-κB plays a key role in the development of human hematologic malignancies, according to a presentation at the recent Peripheral T-cell Lymphoma Forum. Arnold Rabson, MD, of The Cancer Institute of New Jersey, presented results concerning the relationship between the constitutive activation of the cytoplasmic transcription factor NF-κB and proliferation of T-cell NHL, adult T-cell leukemia, B-cell lymphoma, multiple myeloma, and cutaneous T-cell lymphoma. [Read Article]

Lack of experimental models impairs progress for treating T-cell lymphomas

Frieda Pearce, PhD Read Article
Published: 10/02/08

Pier Paolo Piccaluga, MD, PhD
Pier Paolo Piccaluga, MD, PhD

Researchers cite a lack of experimental models as one of the main obstacles to better understanding the complex set of diseases known as T-cell lymphomas. At the recent Peripheral T-cell Lymphoma Forum, Pier Paolo Piccaluga, MD, PhD, stressed the need for clinician collaboration to increase the availability of patient tissue. Owen A. O’Connor, MD, PhD, discussed the lack of animal models available to assess prognosis and develop novel therapies for T-cell lymphomas. [Read Article]

Denileukin diftitox as treatment of PTCL

Jen Smith Read Article
Published: 09/29/08

Francine M. Foss, MD
Francine M. Foss, MD

Denileukin diftitox shows promise as treatment of PTCL, according to presentations given at the Peripheral T-cell Lymphoma Forum. Nam Dang, MD, PhD, of University of Nevada School of Medicine, explained the rationale for using denileukin diftitox to treat PTCL. And Francine M. Foss, MD, of Yale Cancer Center, reported results of a study evaluating denileukin diftitox plus CHOP in patients with aggressive PTCL. The Peripheral T-cell Lymphoma Forum took place September 18-20 in Washington, DC. [Read Article]

Early results of international T-cell registry

Jen Smith Read Article
Published: 09/26/08

Julie M. Vose, MD
Julie M. Vose, MD

Clinicians have realized that international cooperation may be the best way to improve their understanding of T-cell lymphomas. They are therefore taking steps to enhance the worldwide exchange of clinical information. At the Peripheral T-cell Lymphoma Forum, Julie M. Vose, MD, of the University of Nebraska in Omaha, reported preliminary results from a recently formed international registry of T-cell lymphoma patients.  [Read Article]

Upfront ASCT feasible in T-cell lymphoma

Jen Smith Read Article
Published: 09/26/08

Peter Reimer, MD
Peter Reimer, MD

Although limited, clinical data seem to suggest that autologous stem cell transplant (ASCT) is suitable as upfront therapy in patients with T-cell lymphoma. At the Peripheral T-cell Lymphoma Forum, two speakers presented data demonstrating the outcome of ASCT when performed in T-cell lymphoma patients in first partial or complete remission. Both Peter Reimer, MD, and Francesco d’Amore, MD, PhD, concluded that upfront ASCT is a feasible option for these patients.  [Read Article]

PTCL consortium making progress slowly but surely

Jen Smith Read Article
Published: 09/26/08

Ranjana Advani, MD
Ranjana Advani, MD

Nearly 2 years ago, a group of North American researchers decided to create a consortium to foster collaboration and communication among PTCL researchers. At the Peripheral T-cell Lymphoma Forum, Ranjana Advani, MD, of Stanford University Medical Center, discussed the progress the group—called the North American PTCL Consortium (NATC)— has made since its inception. [Read Article]

Most effective first-line therapy for T-PLL

Jane Rosen, PhD Read Article
Published: 09/25/08

Alemtuzumab is the most effective first-line therapy for T-cell prolymphocytic leukemia (T-PLL), according to a presentation at the Peripheral T-cell Lymphoma Forum. Alemtuzumab is effective when administered alone or in combination with purine analogs, should be administered intravenously as opposed to subcutaneously, and is also effective as a second-line therapy in T-PLL, said Claire Dearden, MD, FRCP, FRCPATH, of The Royal Marsden Hospital. [Read Article]

NHL misclassified more often than previously thought

Jen Smith Read Article
Published: 09/24/08

Patients with rare forms of NHL are misdiagnosed more often than previously anticipated, which can translate to improper disease treatment and inferior patient outcomes. At the recent Peripheral T-cell Lymphoma Forum, Julie M. Vose, MD, presented results from the International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study. The study indicated that review by an expert hematopathologist is necessary to accurately define subtypes of PTCL and NKTCL and allow for proper treatment of these diseases. [Read Article]

Pralatrexate demonstrates superior efficacy in T-cell lymphomas

Jen Smith Read Article
Published: 09/22/08

The novel folate analog pralatrexate could potentially replace CHOP as upfront therapy in T-cell lymphomas, according to a presentation at the Peripheral T-cell Lymphoma Forum. Owen O’Connor, MD, PhD, said pralatrexate demonstrates significant preclinical and clinical activity in T-cell lymphomas. The drug is more potent than methotrexate, demonstrates marked synergy with gemcitabine, and can elicit more durable responses than conventional chemotherapy. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}